No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
NBIX250117P180000
- 0.00
- 0.000.00%
15min DelayClose Dec 20 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest180.00Strike Price0.00Turnover0.00%IV-32.92%PremiumJan 17, 2025Expiry Date44.58Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Neurocrine Is Maintained at Overweight by Barclays
Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $160
Wedbush Raises Price Target on Neurocrine Biosciences to $154 From $148, Keeps Outperform Rating
Barclays Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165
Express News | Neurocrine Biosciences Inc : Jefferies Raises Target Price to $168 From $158
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?